Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - PROVECTUS BIOPHARMACEUTICALS, INC. | Financial_Report.xls |
| EX-23 - EX-23 - PROVECTUS BIOPHARMACEUTICALS, INC. | d862762dex23.htm |
| EX-31.2 - EX-31.2 - PROVECTUS BIOPHARMACEUTICALS, INC. | d862762dex312.htm |
| EX-31.1 - EX-31.1 - PROVECTUS BIOPHARMACEUTICALS, INC. | d862762dex311.htm |
| 10-K - 10-K - PROVECTUS BIOPHARMACEUTICALS, INC. | d862762d10k.htm |
| EX-32 - EX-32 - PROVECTUS BIOPHARMACEUTICALS, INC. | d862762dex321.htm |
Exhibit 3.2
CERTIFICATE OF AMENDMENT
TO THE CERTIFICATE OF INCORPORATION
of
PROVECTUS BIOPHARMACEUTICALS, INC.
PROVECTUS BIOPHARMACEUTICALS, INC. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify:
| 1. | The name of the Corporation is Provectus Biopharmaceuticals, Inc. |
2. The Certificate of Incorporation of the Corporation is amended by deleting the introductory sentence of Article IV thereof and substituting the following in its place:
“The total number of shares which the Corporation shall have authority to issue is 325,000,000 shares of capital stock, of which 300,000,000 shares shall be designated Common Stock, $0.001 par value per share (“Common Stock”), and 25,000,000 shall be designated Preferred Stock, $0.001 par value per share (“Preferred Stock”).”
| 3. | This Certificate of Amendment to the Certificate of Incorporation has been duly adopted in accordance with the provisions of Section 242 of the DGCL. |
IN WITNESS WHEREOF, said Corporation has caused this Certificate of Amendment to the Certificate of Incorporation to be signed by the authorized officer this 16th day of June, 2014.
| PROVECTUS BIOPHARMACEUTICALS, INC. | ||
| By: | /s/ Peter R. Culpepper | |
| Peter R. Culpepper, Chief Financial Officer | ||
| and Chief Operating Officer | ||